BIIB vs VRTX

• BIIBBuy more27%

  Biogen's report on Oct 28 beat profit forecasts by 27%, and analysts expect profit to grow 30% next year.

• VRTXBuy moresales growth, past year10%

  Vertex Pharmaceuticals' sales grew 10% over the past year, and three more analysts rate it a buy than three months ago.

Percent return

• BIIB+58.81%
• VRTX+27.45%

1M6MYTD1Y5YMax

Nov 11, 2025 to Nov 11, 2026

Where they differ

VRTX leads on 4 of 6

BIIBVRTX

• Company size: BIIB $30.0B, VRTX $122B.
  $30.0BCompany sizebigger$122B
• Sales growth, 1 yr: BIIB +2.3%, VRTX +10%. VRTX is ahead.
  +2.3%Sales growth, 1 yr+10%
• Price for $1 of next year's profit: BIIB $17, VRTX $29. BIIB is ahead.
  $17cheaperPrice for $1 of next year's profit$29
• Profit per $1 of sales: BIIB 24¢, VRTX 38¢. VRTX is ahead.
  24¢Profit per $1 of sales38¢
• Cash minus debt: BIIB −$6.50B, VRTX +$3.34B. VRTX is ahead.
  −$6.50BCash minus debt+$3.34B
• Price change, 1 yr: BIIB +59%, VRTX +27%. BIIB is ahead. S&P 500 +12%.
  +59%Price change, 1 yr+27%
• How much the price swings: BIIB 35%, VRTX 28%. VRTX is ahead.
  35%How much the price swingssteadier28%

Measure	BIIBBiogen	VRTXVertex Pharmaceuticals
Price and returns
Price	$253.49	$547.18
Today	Best in this row: +0.09%	−0.13%
1 month	Best in this row: +12.27%	+7.24%
3 months	Best in this row: +24.33%	+3.31%
This year	Best in this row: +43.99%	+20.66%
1 year	Best in this row: +58.81%	+27.45%
5 years	−4.94%	Best in this row: +194.31%
From 52-week high	−0.5%	−2.1%
How much it swings (90 days)	35%	Best in this row: 28%
Valuation
Market value	$30.0B	$122B
Price vs last year's earnings	Best in this row: 21.9×	28.6×
Price vs next year's expected earnings	Best in this row: 16.9×	29.0×
Price vs earnings, adjusted for growth	2.12×	Best in this row: 2.11×
Price to sales	Best in this row: 3.6×	10.7×
Price vs cash it brings in	Best in this row: 17.7×	43.3×
Company value vs operating profit	Best in this row: 13.1×	26.5×
Growth
Revenue growth, 1 year	+2.3%	Best in this row: +10.5%
Revenue growth a year, last 3 years	−0.9%	Best in this row: +10.3%
Earnings per share growth, last year	−7.9%	Best in this row: +546.5%
Earnings per share growth expected next year	Best in this row: +29.9%	+10.4%
Profitability
Kept from sales after making the product	Best in this row: 75.8%	54.8%
Kept as operating profit	23.5%	Best in this row: 37.8%
Kept as final profit	3.4%	Best in this row: 30.7%
Kept as spare cash	20.1%	Best in this row: 24.7%
Profit on shareholders' money	1.9%	Best in this row: 20.8%
Profit on all money put in	7.4%	Best in this row: 23.1%
Balance sheet
Net cash (cash minus debt)	−$6.50B	Best in this row: $3.34B
Debt for each $1 of shareholders' money	0.41×	Best in this row: 0.31×
Short-term assets per $1 of bills due	1.95×	Best in this row: 2.34×
Our readPro
Our call	Buy more	Buy more
Why	Biogen's report on Oct 28 beat profit forecasts by 27%, and analysts expect profit to grow 30% next year.	Vertex Pharmaceuticals' sales grew 10% over the past year, and three more analysts rate it a buy than three months ago.
Where the price sits	in the full report	in the full report
Our overall score (out of 100)	60	Best in this row: 73
Our value score	Best in this row: 70	60
Our growth score	40	Best in this row: 74
Our quality score	70	Best in this row: 90
Our price trend score	Best in this row: 70	70
Earnings and analysts
Analyst consensus	Buy	Buy
To average analyst target	+4.9%	Best in this row: +12.6%
Average analyst target	$266.00	$616.37
Analysts rating it a buy	69%	Best in this row: 81%
Buy ratings added, 3 months	+2	Best in this row: +3
Analysts covering	25	22

VRTX: faster sales growth

Our pick of these: Vertex Pharmaceuticals

Buy more75/100

Sales growth +10.5% vs +2.3%

BIIB +2.3%, VRTX +10.5%.

BIIB+2.3%

VRTX+10.5%

Forward P/E per point of sales growth 2.77 vs 7.33

BIIB 7.33, VRTX 2.77.

BIIB7.33

VRTX2.77

+12.6% to the average analyst target, vs +4.9%

BIIB +4.9%, VRTX +12.6%.

BIIB+4.9%

VRTX+12.6%

Where it loses: BIIB has a better past year, +58.8% vs +27.4%

• 2ndBIIBBuy more25/100Would need faster sales growth, +2.3% vs +10.5%

Prices as of yesterday, 3:59 PM ET. A view, not advice.